On the Horizon: A Global Multidisciplinary Perspective on Delivering Emerging Therapies for Patients with BCG-Naïve High-Risk NMIBC
Abstract Patients with high-risk non-muscle invasive bladder cancer (NMIBC) are generally treated with transurethral resection of the bladder tumor followed by intravesical bacillus Calmette-Guérin (BCG), the current standard of care. However, recurrence or progression is common and may result in pa...
Saved in:
| Main Authors: | Bernadett E. Szabados, Félix Guerrero-Ramos, Enrique Grande, Petros Grivas, Viktor Grünwald, Marta Carpintero Miguel, Syed A. Hussain, Girish S. Kulkarni, Ana Lisa Wilson, Neal D. Shore, Srikala S. Sridhar, Mary Hoyt, Samantha Strumeier, Jennifer Sutton, Julia Brinkmann, Rosemary E. Teresi, Tilman Todenhöfer |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2025-04-01
|
| Series: | Oncology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40487-025-00334-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Intravesical BCG: Possible Protective Impact Against COVID-19 in NMIBC Patients
by: Gabriel GLUCK, et al.
Published: (2020-06-01) -
Urinary microbiota changes among NMIBC patients during BCG therapy: comparing BCG responders and non-responders
by: Toni Boban, et al.
Published: (2025-03-01) -
Intravesical chemotherapy in BCG waiting period may prolong time to recurrence for high-risk NMIBC patients
by: Zhen Li, et al.
Published: (2025-02-01) -
Outcomes in BCG failure: Outcome from a single centre UK experience
by: Elizabeth Day, et al.
Published: (2025-05-01) -
Does the Decrease in Neutrophil-lymphocyte Ratio after BCG Treatment Be a Prognostic Marker for NMIBC?
by: Aykut Başer
Published: (2020-12-01)